Infection with the intracellular protozoan parasite *Leishmania donovani* causes a potentially fatal disease wherein macrophages of the viscera including the spleen, liver, and bone marrow become infected, leading to splenomegaly and hepatomegaly. Resistance to infection with *L. donovani* in the well-characterized BALB/c mouse model is associated with an interleukin 1 (IL-1)--driven type 1 response, leading to the production of interferon-γ (IFN-γ) and activation of macrophages \[[@bib1]\]. In contrast, overproduction of interleukin 10 (IL-10) is associated with disease exacerbation \[[@bib2], [@bib3]\]. Control of parasite growth in the liver is associated with the ability to produce sterile granulomas \[[@bib4]\], a mechanism driven by T-cell--derived IFN-γ \[[@bib2]\]. Paradoxically, studies using interleukin 4 (IL-4)^-/-^ mice have also demonstrated an important protective role for this cytokine during primary infection \[[@bib4]\]. Enhanced susceptibility of IL-4^-/-^ mice was associated with downregulated type 1 responses \[[@bib5]\] and markedly retarded granuloma maturation \[[@bib4]\].

A number of chemotherapeutic options are available to treat visceral leishmaniasis. Pentavalent antimony (sodium stibogluconate \[SSG\]) is composed of stibonic and gluconic acids \[[@bib6]\] and has been among the most commonly used antileishmanial drugs. Several studies have highlighted the importance of T lymphocytes and associated cytokines in the efficacy of SSG treatment, indicating that the host cell--mediated immune response is an important factor in SSG chemotherapy \[2, 5, 7\]. Animal studies have also demonstrated that successful treatment of visceral leishmaniasis with SSG requires the presence of both CD4^+^ and CD8^+^ T cells \[[@bib7]\] accompanied by the type 1 cytokines interleukin 12 (IL-12) and IFN-γ \[[@bib2]\]. Our previous studies of primary *L. donovani* infection using IL-4^-/-^ BALB/c mice demonstrated that IL-4 plays a protective role and facilitates successful chemotherapy by promoting a type 1 response \[[@bib4], [@bib5]\]. Additional studies of the primary disease model demonstrated that interleukin 4 receptor α (IL-4Rα)^-/-^ BALB/c mice were significantly more susceptible to *L. donovani* infection than were IL-4^-/-^ mice, as measured by liver parasite burdens early in infection \[[@bib4]\]. Because the IL-4 and interleukin 13 (IL-13) receptors share the IL-4Rα subunit, this clearly suggests a role for IL-13 in the protective response. Studies using IL-13^-/-^ BALB/c mice have been less conclusive, and although IL-13 deficiency was identified as promoting granuloma maturation, which is correlated with protection, no effect of IL-13 deficiency on parasite burdens was observed \[[@bib8]\]. Indeed, a study using mice deficient in the IL-13 decoy receptor IL-13Rα2, and consequently producing excess functional IL-13, indicated that IL-13 inhibited a type 1 response and promoted disease \[[@bib9]\]. Surprisingly, IL-13 was found to have little effect on SSG chemotherapy in either study \[8, 9\], despite the demonstrated involvement of the related cytokine IL-4 in this process \[[@bib5]\]. However, previous studies on cutaneous leishmaniasis have demonstrated that although IL-13 can substitute for IL-4 in its absence, IL-13 can also have independent properties \[[@bib10]\].

Consequently, to more specifically characterize the role of IL-13 and its functional targets during infection with *L. donovani,* we have used IL-13^-/-^, IL-4Rα^-/-^, and macrophage/neutrophil-specific IL-4Rα^-/-^ BALB/c mice both during primary infection with *L. donovani* and following SSG chemotherapeutic intervention. We demonstrate that IL-13 plays a significant role in controlling hepatic visceral leishmaniasis both during primary infection and following SSG chemotherapy by promoting a type 1 response and hepatic granuloma maturation. Furthermore, using macrophage/neutrophil-specific IL-4Rα^-/-^ BALB/c mice \[[@bib11]\], we demonstrate that the protective influence of IL-13 is independent of these cellular targets. Because murine lymphocytes do not possess IL-13 receptors, these results raise intriguing questions regarding the mode of action and cellular targets of this cytokine. Data reported here suggest that IL-13 functions through dendritic cells to promote a protective response.

MATERIALS AND METHODS
=====================

Animals and Parasites
---------------------

We used age- and sex-matched, in-house, inbred IL-13^-/-^ BALB/c mice (20--25 g, female) and their wild-type counterparts along with macrophage/neutrophil-specific IL-4Rα^-/-^ mice and their negative littermates \[[@bib11]\]. We intercrossed IL-4Rα^lox/lox^ BALB/c \[[@bib11]\] mice with BALB/c mice expressing Cre recombinase under the control of the LysM promoter \[[@bib12]\] and then further crossed with IL-4Rα BALB/c mice \[[@bib13]\] to generate hemizygous LysM^cre^IL-4Rα^-/lox^ mice. Polymerase chain reaction genotyping was used to identify LysM^cre^IL-4Rα^-/lox^ mice. LysM^cre^-negative IL-4Rα^-/lox^ BALB/c mice were used as wild-type equivalents. Commercially obtained golden Syrian hamsters (*Mesocricetus auratus*) were used for maintenance of *L. donovani* strains (Harlan Olac)*. L. donovani* strains 200016 and LV82 were used in our study \[[@bib14]\]. Mice were infected on day 0 by intravenous injection (tail vein, no anaesthetic) with 1--2 × 10^7^ *L. donovani* amastigotes \[[@bib15]\]. Animal experiments were performed after institutional ethical review and in accordance with UK Home Office regulations.

In Vivo Studies
---------------

To compare the course of infection in cytokine deficient mice and their wild-type counterparts (*n* = 4 treatment), we infected mice with *L. donovani* and killed them on different days postinfection. In drug studies, infected mice were treated intravenously on days 14 and 15 with phosphate-buffered saline (controls) or SSG solution (Glaxo-Wellcome, equivalent to a final dose of 111 mg Sb^v^/kg), and we determined parasite burdens in control and drug-treated animals at day 40 postinfection.

To determine parasite burdens in the spleen and liver, impression smears were prepared on an individual glass microscope slide for each mouse at experiment termination. We prepared bone marrow smears by exposing the mouse femur, cutting behind the kneecap, and inserting a needle into the bone to retrieve the bone marrow. We smeared each bone marrow sample onto the end of a slide using the needle. We fixed the slides in methanol for 2 minutes, stained them with a 10% Giemsa solution (BDH, VWR International Ltd) for 20 minutes, washed them in tap water, and allowed them to dry. We determined the number of parasites per 1000 host nuclei for each sample at x1000 magnification.

Generation and Stimulation of Bone Marrow--Derived Dendritic Cells
------------------------------------------------------------------

We obtained bone marrow--derived dendritic cells from BALB/c mice (aged 10 wk). We flushed the femurs with 5 mL of Roswell Park Memorial Institute 1640 medium (RPMI 1640), washed the cell suspension, adjusted the bone marrow cell concentration to 5 x10^5^ cells/mL, and cultured the cells in 6-well plates (Corning Costar) at 37°C and 5% CO~2~ in RPMI 1640, 10% vol/vol heat-inactivated fetal bovine serum (FBS, Sigma-Aldrich), 1% vol/vol 2 mM [L]{.smallcaps}-glutamine solution, 1% vol/vol 100 IU/mL penicillin, 100 mg/mL streptomycin (PAA Laboratories, GmbH), and 10% culture supernatant from X63 myeloma cells transfected with mouse GM-CSF cDNA. We added fresh medium to the cell cultures every 3 days, generating many CD11c^+^ dendritic cells largely free from granulocyte and monocyte contamination. We harvested the cells on day 10, seeded them at 5 ×10^4^ cells per well in 96-well tissue culture plates, and treated them with 100 ng/mL recombinant (r)IL-13 (R&D Systems) or 100 ng/mL lipopolysaccharide (LPS). The cells were either preincubated overnight with rIL-13 before being stimulated with LPS for a further 48 hours or incubated with rIL-13 and LPS together for 72 hours. We froze the supernatants at −20°C before we measured IL-12p40 production by ELISA.

Cytokine Production
-------------------

We used enzyme-linked immunosorbent assay (ELISA) to determine IL-4, IL-10, IL-12p40, IL-13, and IFN-γ levels in the sera of *L. donovani*--infected mice, as previously described \[[@bib5]\].

Histology
---------

At termination, we removed sections of liver and fixed them in neutral-buffered formalin, then processed and stained them with Haematoxylin and Eosin (Fisher Scientific). We scored granulomas as infected Kupffer cells (parasitized macrophages), immature (developing granuloma consisting of CD4^+^ and CD8^+^ T cells and monocytes surrounding infected Kupffer cells), mature (more developed than immature granulomas), or sterile (parasite-free granuloma). Granulomas were scored as previously described in a study by Murray \[[@bib16]\].

Statistical Analysis of Data
----------------------------

We analyzed parasite data from in vivo experiments using a 1-way analysis of variance (ANOVA, using log~10~-transformed parasite burden for the liver data). We then analyzed differences between treatments using a Fisher protected least significant difference (PLSD) test with the Statview version 5.0.1 software package. We analyzed cytokine, granuloma, and flow cytometry data using an unpaired *t* test.

RESULTS
=======

Liver Parasite Burdens Are Increased and Granuloma Formation Inhibited in IL-13^-/-^ BALB/c Mice Infected With *L. donovani*
----------------------------------------------------------------------------------------------------------------------------

Parasite burdens in the livers of wild-type and IL-13^-/-^ BALB/c mice infected intraveneously with 1--2 × 10^7^ *L. donovani* amastigotes were enumerated at days 14 and 35 postinfection. At day 14 postinfection, liver parasite burdens were similar in both wild-type and IL-13^-/-^ BALB/c mice ([Figure 1A](#fig1){ref-type="fig"}). Whereas parasite burdens in the livers of wild-type mice had declined by day 35 postinfection, they did not decline over this period in IL-13^-/-^ BALB/c mice, and we found them to be significantly higher (*P* \< .001) in IL-13^-/-^ than in wild-type mice at this time ([Figure 1A](#fig1){ref-type="fig"}). Parasite numbers were also found to be significantly greater in the spleens and bone marrow of *L. donovani*--infected IL-13^-/-^ compared with those found in wild-type BALB/c mice ([Figures 1B](#fig1){ref-type="fig"} and C).

![The *L. donovani* liver *(A)*, spleen *(B)*, and bone marrow *(C)* parasite burdens at days 14 and 35 postinfection following intravenous infection with 1--2 × 10^7^ amastigotes. The data are means ± standard errors for individual mice (*n* = 4) and are representative of 1 of 4 independent experiments.](infdisjir080f1_lw){#fig1}

We also assessed granuloma maturation in livers from wild-type and IL-13^-/-^ mice over this period ([Figures 2A and 2B](#fig2){ref-type="fig"}). We scored granulomas as described previously \[[@bib16]\]: infected Kupffer cells (parasitized macrophages), immature granuloma (consisting of T cells and monocytes surrounding infected Kupffer cells), mature (developed), or sterile (parasite-free) granuloma. IL-13^-/-^ BALB/c mice showed normal early inflammatory responses, with the formation of immature granulomas with similar frequency as wild-type mice on day 14 postinfection ([Figure 2A](#fig2){ref-type="fig"}). Whereas approximately 60% of the inflammatory foci had progressed to mature or sterile granulomas in wild-type mice at day 35 postinfection ([Figures 2B--C](#fig2){ref-type="fig"}), granulomas failed to mature in IL-13^-/-^ mice ([Figures 2B--D](#fig2){ref-type="fig"}) and the histological profile was similar to that of day 14. Because the overall granulomatous response at day 35 is indicative of a good healing response \[[@bib16]\], which is reflected by the reduction in parasite burdens in wild-type mice, these data suggest that host-protective granulomatous responses were inhibited in IL-13^-/-^ mice.

![Granuloma maturation in *L. donovani*--infected wild-type and IL-13^-/-^ mice at days 14 *(A)* and 35 *(B)* postinfection. The data are means ± standard errors for 1 of 4 independent experiments. \**P* \< .05 and \*\**P* \< .01 wild-type versus IL-13^-/-^. Photomicrographs showing the hepatic granuloma response in two *L. donovani*--infected mice, wild-type *(C)* and IL-13^-/-^ *(D)*, at day 35 postinfection. Wild-type mice show well-developed mature granulomas (arrows) surrounding a core of infected Kupffer cells, whereas IL-13^-/-^ mice show abrogated granuloma development characterized by the presence of immature granulomas and amastigotes within the cytoplasm of Kupffer cells at day 35 postinfection (arrows). Magnification x400.](infdisjir080f2_3c){#fig2}

Serum Cytokine Levels Correspond to a Deficient Type-1 Response in *L. donovani* Infected IL-13^-/-^ Compared With Wild-Type BALB/c Mice
----------------------------------------------------------------------------------------------------------------------------------------

IFN-γ is important in controlling granuloma maturation; Murray et al have previously shown that IFN-γ-deficient mice are unable to control parasite burdens and granuloma formation \[[@bib2]\]. We found serum IFN-γ levels at day 35 postinfection to be significantly greater (*P* \< .0001) in *L. donovani*--infected wild-type mice compared with levels in IL-13^-/-^ BALB/c mice ([Figure 3A](#fig3){ref-type="fig"}). We also found *L. donovani* to induce high serum IL-13 levels in *L. donovani*--infected wild-type mice ([Figure 3B](#fig3){ref-type="fig"}). Conversely, both IL-4 and IL-10 serum levels were greater in IL-13^-/-^ mice compared with levels in wild-type mice ([Figure 3C](#fig3){ref-type="fig"} and D respectively). Together these results show a positive association of IFN-γ and IL-13 production with granuloma maturation and a negative association with IL-4 and IL-10 levels. Consistent with these observations, IL-12 serum levels peaked earlier in infection in wild-type mice compared with levels in IL-13^-/-^ mice ([Figure 3E](#fig3){ref-type="fig"}). As well as systemic cytokine levels, the percentage of IFN-γ-secreting CD4^+^ T cells and CD8^+^ T cells was significantly greater in the spleens of wild-type mice than in IL-13^-/-^ mice ([Figure 3F](#fig3){ref-type="fig"}; wild-type mice, 7.9 ± 0.265% CD4^+^ IFN-γ^+^ T cells and 15.5 ± 0.354% CD8^+^ IFN-γ^+^ T cells; IL-13^-/-^ mice, 6.1 ± 0.24% CD4^+^ IFN-γ^+^ T cells and 12.0 ± 0.841% CD8^+^ IFN-γ^+^ T cells).

![Mean serum IFN-γ *(A)*, IL-13 *(B)*, IL-10 *(C)*, and IL-4 *(D)* levels ± standard errors in wild-type and IL-13^-/-^ BALB/c mice (*n* = 4) at day 35, and IL-12 p40/70 *(E)* at days 14 and 35 postinfection with *L. donovani* as measured in individual serum samples by enzyme-linked immunosorbent assay. Representative data from 4 independent experiments are shown. No measurable cytokine levels were observed in sera from uninfected wild-type and IL-13^-/-^mice. Analysis of intracellular IFN-γ expression *(F)* was performed on day 35 postinfection on splenocytes stimulated in the presence of 50 ng/mL phorbol myristate acetate (Sigma-Aldrich) and 500 ng/mL of ionomycin (Sigma-Aldrich) for 4 hours, with the addition of Brefeldin A during the last 2 hours as previously described. The antimouse antibody PerCP-labeled anti-CD4^+^, activated protein C--labeled anti-CD8^+^, peridinin chlorophyll protein--labeled, and activated protein C--labeled IgG isotype controls were used to stain the cell surfaces, and the protein E--labeled anti-mouse IFN-γ and protein E--labeled IgG isotype control were used for intracellular staining. All antibodies were obtained from BD Biosciences. Cells were analyzed with the FACSCanto. The FACsDiva software was used to analyze results. Representative of 2 separate experiments. \**P* \< .05, \*\**P* \< .01 wild-type versus IL-13^-/-^. ND = not detected.](infdisjir080f3_lw){#fig3}

Sodium Stibogluconate Drug Treatment Was Ineffective in IL-13^-/-^ BALB/c Mice and Granulomas Failed to Mature
--------------------------------------------------------------------------------------------------------------

We treated *L. donovani*--infected wild-type and IL-13^-/-^ BALB/c mice with SSG (111 mg Sb^v^/Kg) on days 14 and 15 postinfection, and we compared parasite burdens with those of non--drug-treated control mice at day 40 postinfection. We calculated SSG parasite suppression by comparing each experimental value with the mean control value. As expected, SSG drug treatment was successful in wild-type animals, resulting in 61% suppression of parasite numbers in the liver ([Figure 4A](#fig4){ref-type="fig"}). Interestingly, SSG drug treatment was ineffective in IL-13^-/-^ mice, as parasite burdens at day 40 postinfection were similar to control values.

![Sodium stibogluconate--mediated suppression of parasite burdens in the liver and granuloma maturation in IL-13^-/-^ and wild-type BALB/c mice infected with *L. donovani*. The mean suppression (± standard error \[SE\]) of parasite burdens induced by treatment with 111 mg Sb^v^/kg sodium stibogluconate (SSG) at days 14 and 15 postinfection in the livers of wild-type and IL-13^-/-^ mice was assessed at day 40 postinfection *(A)*. Parasite suppression was measured by comparing each experimental value with the mean control value (*NS* = no suppression). Granuloma maturation in non--drug-treated *(B)* and drug-treated *(C)* *L. donovani*--infected wild-type and IL-13^-/-^ mice at day 40 postinfection was also measured. Paraffin-embedded liver sections from wild-type and IL-13^-/-^ mice (*n* = 4) were stained with haematoxylin and eosin, and granuloma formation per 100 microscopic fields was determined. The data are means (±SE) for 1 of 2 independent experiments. \*\**P* \< .01 wild-type versus IL-13^-/-^.](infdisjir080f4_lw){#fig4}

We assessed granuloma maturation in livers from control and drug-treated mice of both wild-type and IL-13^-/-^ BALB/c strains as we described previously. As expected, wild-type mice demonstrated a significant amount of granuloma maturation whereby there were few infected Kupffer cells remaining without associated inflammation, although immature and, to a lesser extent, mature granulomas were predominant; and some sterile granulomas were also evident ([Figure 4B](#fig4){ref-type="fig"}). In drug-treated wild-type mice, however, there was a significant increase in mature but particularly sterile granulomas compared with granulomas in non--drug-treated animals (*P* \< .001), whereas levels of infected Kupffer cells and immature granulomas were reduced greatly ([Figure 4C](#fig4){ref-type="fig"}). In non--drug-treated IL-13^-/-^ BALB/c mice, granulomas failed to mature as infected Kupffer cells were dominant, and there were few mature and sterile granulomas ([Figure 4B](#fig4){ref-type="fig"}). Furthermore, SSG treatment did not promote any significant granuloma maturation in IL-13^-/-^BALB/c mice ([Figure 4C](#fig4){ref-type="fig"}).

The *L. donovani* Protective Influences of IL-13 Are Independent of Macrophage/Neutrophil Involvement
-----------------------------------------------------------------------------------------------------

Murine lymphocytes are not responsive to IL-13, suggesting that the effects of IL-13 are indirect. Previous studies suggest that in *Listeria monocytogenes* infection, IL-13 drives IL-12 production by monocytes and a protective type 1 response against the infection \[[@bib17], [@bib18]\]. To test the possible role of IL-13--responsive macrophages in the protective responses against *L. donovani*, we used recently established macrophage/neutrophil-specific IL-4Rα^-/-^ BALB/c mice \[11\] for comparative *L donovani* infection studies.

Primary infection of macrophage/neutrophil-specific IL-4Rα^-/-^ mice (LysMcreIL-4Rα^-/lox^) and their control littermates (IL-4Rα^-/lox^) with *L. donovani* resulted in similar liver parasite burdens ([Figure 5A](#fig5){ref-type="fig"}) and granuloma maturation ([Figures 5B and 5C](#fig5){ref-type="fig"}). As previously published, global IL-4Rα^-/-^ BALB/c mice were more susceptible to infection than wild-type mice and have retarded granuloma development \[[@bib4]\] with a histological phenotype similar to IL-13^-/-^ animals (results not shown).

![Liver parasite burdens in wild-type (IL-4Rα^-/lox^) and macrophage/neutrophil-specific IL-4Rα^-/-^ BALB/c (LysM^cre^IL-4Rα^-/lox^) mice at day 40 postinfection with 1--2 × 10^7^ *L. donovani* amastigotes. Part *A* shows representative data from 3 independent experiments. Parts *B* and *C* are light micrographs from an IL-4Rα^-/lox^ mouse and a LysM^cre^IL-4Rα^-/lox^ mouse, respectively, at day 40 postinfection; they show mature granulomas (arrows) consisting of well-developed mononuclear cell mantles (magnification 400x).](infdisjir080f5_3c){#fig5}

SSG drug-induced suppression of parasite burdens in the liver was equivalent in control (59%) and macrophage/neutrophil-specific IL-4Rα^-/-^ (55%) mice at day 40 postinfection ([Figure 6A](#fig6){ref-type="fig"}), indicating that treatment was successful in both mouse strains. In agreement, compared with non-drug-treated mice ([Figure 6B](#fig6){ref-type="fig"}), both drug-treated control mice and macrophage/neutrophil-specific IL-4Rα^-/-^ mice ([Figure 6C](#fig6){ref-type="fig"}) showed a significant increase (*P* \< .01 and *P* \< .001 respectively) in sterile granulomas ([Figure 6B](#fig6){ref-type="fig"}).

![The mean suppression (±standard error) of liver parasite burdens and granuloma induction in the livers of wild-type (IL-4Rα^-/lox^) and macrophage/neutrophil-specific IL-4Rα^-/-^ (LysM^cre^IL-4Rα^-/lox^) mice at day 40 postinfection. These are representative data from 2 independent experiments: liver parasite burdens *(A)*, and granuloma maturation in control *(B)* and drug-treated *(C)* *L. donovani*--infected IL-4Rα^-/lox^ and LysM^cre^IL-4Rα^-/lox^ mice at day 40 postinfection. Mice were treated with phosphate-buffered saline (controls) or 111mg Sb^v^/kg sodium stibogluconate at days 14 and 15 postinfection. A significant increase in sterile granulomas was observed between control and drug-treated mice with *P* \< .01 and *P* \< .001 for IL-4Rα^-/lox^ and LysM^cre^IL-4Rα^-/lox^ mice, respectively. \**P* \< .05 drug-treated wild-type (IL-4Rα^-/lox^) versus drug-treated macrophage/neutrophil-specific IL-4Rα^-/-^ (LysM^cre^IL-4Rα^-/lox^).](infdisjir080f6_lw){#fig6}

IL-13 Primes Dendritic Cells for IL-12 Production
-------------------------------------------------

Previous studies have demonstrated that IL-4 can prime dendritic cells for IL-12 production and a protective immune response against *Leishmania major* \[[@bib19], [@bib20]\]. Because IL-13 also signals through the IL-4Rα chain and has similar functions to IL-4, we tested the possibility that IL-13 was also able to instruct dendritic cells for IL-12 production. We preincubated dendritic cells with rIL-13 either prior to or at the same time as LPS stimulation and analyzed the supernatants for IL-12p40 production by ELISA. Preincubation of dendritic cells with rIL-13 induced significantly increased levels of IL-12 production compared with levels from LPS stimulation alone (*P* \< .0021, [Figure 7](#fig7){ref-type="fig"}). Indeed, preincubation of dendritic cells with rIL-13 was necessary to induce upregulation of IL-12 production following LPS stimulation because incubation of dendritic cells with rIL-13 and LPS together did not lead to significantly increased IL-12 levels compared with levels produced from LPS stimulation alone (*P* \< .0625, [Figure 7](#fig7){ref-type="fig"}).

![Effect of recombinant interleukin 13 and lipopolysaccharide stimulation on interleukin 12 production by dendritic cells. Dendritic cells were either (a) incubated for 72 hours with lipopolysaccharide (LPS) alone (100 ng/mL), recombinant interleukin 13 (rIL-13) alone (100 ng/mL), or LPS and rIL-13 together, or (b) preincubated with rIL-13 overnight and then stimulated with LPS for a further 48 hours. Supernatants were frozen at −20°C before analysis for IL-12p40 by enzyme-linked immunosorbent assay. Preincubating with rIL-13 prior to LPS stimulation induced a significant increase in IL-12p40 production by dendritic cells compared with LPS stimulation alone (*P* \< .0021) or incubation with rIL-13 and LPS together (*P* \< .0001). pi = preincubated.](infdisjir080f7_lw){#fig7}

DISCUSSION
==========

Our previous studies identified a protective role for IL-4 and IL-4Rα signaling during *L. donovani* infection \[[@bib4], [@bib5]\]. Furthermore, the increased susceptibility to *L. donovani* of IL-4Rα^-/-^ mice compared with that of IL-4^-/-^ BALB/c mice, as measured by hepatic parasite burdens \[[@bib4]\], suggested a protective role for IL-13 also, because activities of both IL-4 and IL-13 are dependent on the expression of IL-4Rα. Whereas serum IFN-γ levels were similar in wild-type and IL-4^-/-^ *L. donovani*--infected BALB/c mice, we measured no detectable IFN-γ in IL-4Rα^-/-^ animals, which suggests that IL-13 alone or IL-13 and IL-4 together are essential for optimal development of type 1 responses and immunity against this parasite \[[@bib4]\]. This study confirmed the suggestion by demonstrating that IL-13 promotes a protective response against visceral leishmaniasis, as parasite burdens were significantly enhanced and granuloma maturation was significantly inhibited in IL-13^-/-^ BALB/c mice compared with those in wild-type mice. Concomitantly, type 1 responses, as measured by IFN-γ production, were significantly inhibited; type 2 responses, as measured by IL-4 and IL-10 levels, were significantly enhanced in *L. donovani*--infected IL-13^-/-^ BALB/c mice compared with responses in their wild-type counterparts. This would suggest that IL-13 has a major role in regulating type 1 responses and resistance to *L. donovani.*

The Th2-potentiating role normally associated with IL-13 seems intuitively at odds with our results. However, some studies have demonstrated that IL-4 and IL-13 indirectly drive protective type 1 responses. For example, IL-13 has previously been shown to prime monocytes for IL-12 production \[[@bib17]\] and drive a protective type 1 response during listeriosis \[[@bib18]\]. Furthermore, a recent study on *L. donovani* that failed to demonstrate a protective role, as measured by hepatic parasite burdens, for IL-13 during *L. donovani* primary infection or following chemotherapy infection demonstrated that this cytokine promoted granuloma formation and IFN-γ production during primary infection \[[@bib8]\]. Thus, this study, like our own, clearly identified a switch toward a type 1 immune response bias. Differences between the studies could reflect the different parasite strains used in the separate laboratories. However, we had similar results in our studies with 3 separate strains, including an SSG-resistant strain \[[@bib15]\].

Previous studies on *L. major* infection have also demonstrated a protective role for IL-13, as IL-4Rα^-/-^ BALB/c mice, unlike IL-4^-/-^ mice, were unable to avoid disease dissemination and visceralization \[[@bib13]\]. Because murine lymphocytes do not have receptors for IL-13, other cell populations must be instructed for a protective role by this cytokine in the absence of IL-4. Indeed, a recent study using CD4^+^ T-cell--specific IL-4Rα^-/-^ mice has demonstrated that these mice, unlike global IL-4Rα^-/-^ mice, are as resistant to *L. major* as C57BL/6 animals. Consequently, Radwanska et al concluded that IL-4/IL-13 responsive non-CD4 T cells induce protection against *L. major* in the absence of CD4^+^ T cells responding to IL-4 \[[@bib19]\]. Because Flesch et al had previously shown that IL-13 primes monocytes for IL-12 production \[[@bib17]\] and drives a protective type 1 response during listeriosis \[[@bib18]\], we examined *L. donovani* disease progression in macrophage/neutrophil-specific IL-4Rα^-/-^ BALB/c mice. We found macrophage/neutrophil-specific IL-4Rα^-/-^ mice to be no more susceptible to infection with *L. donovani* than their wild-type littermates were. Over a number of experiments we noted an indication, although generally not significant, that granuloma maturation was more precocious in macrophage/neutrophil-specific IL-4Rα^-/-^ *L.* *donovani*--infected BALB/c mice especially following chemotherapy. This clearly suggests that the protective role we have demonstrated for IL-13 during *L. donovani* infection is not due to the activity of this cytokine, or indeed IL-4, on macrophage/neutrophil populations. Hölscher et al found that *L. major* disease progression was inhibited in macrophage/neutrophil-specific IL-4Rα^-/-^ BALB/c mice compared with progression in wild-type animals; their study indicated that IL-13/IL-4 functioned to enhance disease progression by the induction of alternative macrophage activation \[[@bib21]\]. Our results in this study neither rule out nor confirm whether alternative macrophage activation contributes to susceptibility to *L. donovani*. However, alternative macrophage activation could explain the transiently elevated parasite burdens and impaired granuloma maturation in the presence of excess IL-13 in IL-13Rα2^-/-^ *L. donovani*--infected mice \[[@bib9]\]. Consequently, the protective effects, as opposed to disease-exacerbatory effects, of IL-4/IL-13 during both *L. major* and *L. donovani* infections are due to cell populations other than macrophages or neutrophils. Dendritic cells, for example, would be strong candidates because they play pivotal roles in granuloma formation \[[@bib22]\], and an elegant study has previously shown IL-4 to induce dendritic cell IL-12 production and to generate a T-helper 1 (Th1) response and protection against *L. major* \[[@bib20]\]. Furthermore, Ghosh et al found that IL-4--matured bone marrow--derived dendritic cell--based immunotherapy significantly enhances chemotherapy against murine visceral leishmaniasis \[[@bib23]\]. They also found that IL-13 can induce dendritic cell IL-12 production in vitro when used to prime dendritic cells prior to LPS stimulation. The ability of IL-13 to influence dendritic cells in this way may play an important role in enhancing granuloma formation and reducing parasite burdens during *L. donovani* infection.

In addition to being more susceptible than wild-type mice to primary infection with *L. donovani*, IL-13^-/-^ animals responded less well to SSG chemotherapy, as in fact did IL-4^-/-^ BALB/c mice in a previous study \[[@bib5]\]. This would again suggest that IL-4 and IL-13 are playing similar protective roles during *L. donovani* infection. However, as serum IL-4 levels in *L. donovani*--infected IL-13^-/-^ BALB/c mice were significantly higher than levels in wild-type animals, this would suggest that IL-13 could be playing a role independently of IL-4. Using IL-4^-/-^ mice, studies of asthma \[[@bib24]\], schistosomes \[[@bib25]\], and *Nippostrongulas braziliensis* \[[@bib26]\], as well as *L. major* \[[@bib10]\] have demonstrated that IL-13, which has the ability to substitute in part for IL-4, has independent properties or plays a more significant role than IL-4 in various functions. These functions include worm expulsion of *N. braziliensis* \[[@bib26]\], effector activity in asthma \[[@bib24], [@bib27]\], and hepatic fibrosis and granuloma formation in the pathology associated with schistosomiasis \[[@bib25]\]. Paradoxically, although IL-13 appears to be the main mediator of a type 2 immune response, our data suggest that this cytokine is also crucial in generating the granuloma-inducing type 1 immune response associated with protection against *L. donovani.* Nevertheless, in a previous coinfection study \[[@bib28]\], schistosome egg granulomas were found to provide safe havens for the multiplication of *L. donovani* amastigotes, even in the presence of functional anti--*L. donovani* Th1 responses.

Together, our results demonstrate that IL-13 overall plays a beneficial role during *L. donovani* infection independent of a direct role for lymphocytes, macrophages, or neutrophils and is important in the generation of cell-mediated immunity. Preliminary evidence implicates the dendritic cell as a potential target for the IL-13 dependent protective response against *L. donovani.* However, final confirmation will be dependent on the generation of CD11c-specific IL-4Rα^-/-^ mice.
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